INFE.PA Compagnie Industrielle (EURONEXT) €71.00 Jan 2026: oversold bounce
INFE.PA stock is trading at €71.00 intraday on EURONEXT on 22 Jan 2026, presenting a clear oversold bounce setup to monitor. Short-term momentum looks weak after a 3-month drop of 14.46%, but fundamentals show cash buffer and a low PE that can support a tactical rebound. We outline trade triggers, valuation context, and realistic targets for traders watching this small-cap industrial.
INFE.PA stock intraday snapshot and bounce thesis
Price action: INFE.PA stock sits at €71.00 with a day range locked at €71.00 intraday and only 16.00 shares traded so far. Low liquidity increases volatility on any buy interest and supports a fast bounce if buyers step in.
Bounce thesis: The oversold bounce case relies on mean-reversion toward the 50-day average (€75.04) and the 200-day average (€65.85). A first resistance cluster near €75.00–€78.00 offers the initial profit-taking zone for short-term traders.
INFE.PA stock fundamentals and valuation
Valuation: Compagnie Industrielle et Financière d’Entreprises reports EPS €6.35 and a trailing PE of 11.18, below the Industrials sector average PE of 25.37, implying value relative to peers. Market cap stands at €83,492,663.00 with 1,175,953 shares outstanding.
Cash and dividends: Cash per share is robust at €29.94, and the most recent dividend per share is €11.33, implying a high dividend yield reported at 15.96%. Payout ratio is 20.20%, signalling earnings cover dividends. These figures support the stock’s defensive value profile but require scrutiny for sustainability.
INFE.PA stock technicals and liquidity risks
Liquidity and momentum: Average daily volume is 85.00 versus today’s 16.00, producing a relative volume of 0.19. Thin trading makes intraday moves exaggerated and increases execution risk for larger orders.
Technicals: Price is below the 50-day average (€75.04) but above the 200-day average (€65.85), suggesting mixed trend. The recent 3-month decline of 14.46% sets the oversold context; a pullback above €75.00 would confirm a short-term recovery.
INFE.PA stock trade plan and price targets
Tactical setup: For an oversold bounce play, consider a scaled entry between €69.00 and €71.00 with a stop-loss at €65.00 to limit downside on low liquidity. Target €78.00 as a first take-profit zone and €85.00 if broader market support returns.
Risk-reward: Targeting €78.00 from €71.00 implies a near-term upside of 9.86% while a stop at €65.00 limits downside to 8.45%. Use small position sizes given volume constraints.
INFE.PA stock risks, catalysts, and sector context
Key risks: High days sales outstanding at 152.94 days increases working-capital risk for engineering and construction firms. Thin float and low daily volume amplify downside on negative news.
Catalysts and context: Positive catalysts include contract awards or improved receivables conversion. INFE.PA operates in Industrials, where the sector YTD performance is modest; the company’s low PE versus sector averages may attract value buyers if macro risks ease.
Meyka AI grade and INFE.PA stock forecast
Meyka AI rates INFE.PA with a score out of 100: 69.72 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a 1-year target of €74.29 versus the current price €71.00, implying an upside of 4.63%. Forecasts are model-based projections and not guarantees. Use this as one input in a balanced risk plan.
Final Thoughts
INFE.PA stock at €71.00 intraday on EURONEXT on 22 Jan 2026 shows a classic oversold bounce setup: attractive relative valuation with PE 11.18, strong cash per share (€29.94), and a sizeable dividend per share (€11.33). Low liquidity and long receivables remain the main operational risks. For tactical traders we outline a scaled entry between €69.00 and €71.00, stop-loss near €65.00, and first profit target around €78.00. Meyka AI’s forecast model projects €74.29, about 4.63% above today’s price; treat that as a measured, model-based target, not a guarantee. Overall, the stock fits a cautious oversold bounce trade with strict risk controls and small position sizing. For more, see the Meyka stock page and monitor contract news or receivables improvement as triggers
FAQs
Is INFE.PA stock a buy for an oversold bounce?
INFE.PA stock offers a tactical oversold bounce opportunity based on valuation and cash metrics. Use a small position, entry near €69.00–€71.00, and a stop at €65.00. Low liquidity increases execution risk.
What are the key financials to watch for INFE.PA stock?
Track EPS (€6.35), PE (11.18), cash per share (€29.94), dividend per share (€11.33), and days sales outstanding (152.94). Improvements in receivables and contract flow are positive catalysts.
What price targets and forecast exist for INFE.PA stock?
Meyka AI’s forecast model projects €74.29 in one year, an implied upside of 4.63% versus €71.00. Tactical targets: €78.00 first, €85.00 extended. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
